The following treatments are recommended to be available for non-hospitalised adults and children with COVID-19 treated in accordance with the criteria set out in this document. This policy applies to non-hospitalised patients with COVID-19 who are symptomatic and showing no evidence of clinical recovery and covers the following treatment options:

• First-line: nirmatrelvir plus ritonavir (antiviral)
• Second-line: remdesivir (antiviral)
• Third-line: molnupiravir (antiviral)